Safety andManagement ofSorafenib inTreatment of 31 Patients with Metastatic Renal CellCarcinoma

Objective To evaluate the safety ofChinese patients withmetastatic renal cell carcinoma (mRCC)treatedby Soratenib, investigate the toxicities and discuss the management. Methods From Apr2006 to Dec2008, wetreated 31 patients of mRCC with Sorafenib. All of the patients received Sorafenib 400mg, twice daily, continuous intake, twoof themreceived dose enlargement from 800mg/d to 1200mg/d, oneof them combined with immunotherapy. Results The most frequently occurring drug-related adverse events (any grade) were gastrointestinal symptom 22(71.0%), hand-foot syndrome 17(54.8%), fatigue 13(42.0%), hypertension 7(22.6%), dysfunction of liver 3(9.7%), only 4(12.9%) patients had serious drug related adverse events. Conclusion Although there was much drug related adverse events due to Sorafenib, most patients had good tolerance to it with reasonable measure and treatment to prevent and treat adverse events.